MiNK Therapeutics stock initiated at buy by H.C. Wainwright
H.C. Wainwright initiated coverage on MiNK Therapeutics (INKT) with a buy rating and $38 price target, citing potential upside from $10.79. The biotech firm reported a narrowed Q2 2026 net loss of $3.1M, better than estimates. Its lead asset, agenT-797, is in Phase 2b/3 trials for ARDS, with interim data expected in late 2027.
How this was made
The 30-second read
Why it matters
The new buy rating and $38 target highlight strong upside potential, especially given recent Q2 loss beat and cash position.
Market read
Analyst initiation provides fresh catalyst for INKT, potentially driving buying interest.
Timing
pre‑market today
Background
MiNK Therapeutics (NASDAQ:INKT) is a clinical‑stage biotech developing off‑the‑shelf iNKT cell therapies.
Ticker impact
H.C. Wainwright initiated coverage with a buy rating and a $38 price target, up from the current $10.79 price.
likely upward pressure as the market prices in the new target
Buy rating and a target more than three times the current price provide a clear catalyst for buying interest.
Market effects
May boost sentiment toward clinical‑stage biotech stocks.
Limited to U.S. biotech sector.
Low
Key entities
- companyMiNK Therapeutics
Clinical‑stage biotech developing iNKT therapies.
- analystH.C. Wainwright
Initiated coverage with a buy rating.
